Literature DB >> 28141992

CARs Move To the Fast Lane.

Marco L Davila1, Eirini P Papapetrou1.   

Abstract

Year:  2016        PMID: 28141992      PMCID: PMC3944338          DOI: 10.1038/mt.2014.8

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  11 in total

1.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Authors:  James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

2.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors:  David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

3.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Authors:  Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

4.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

Authors:  Barbara Savoldo; Carlos Almeida Ramos; Enli Liu; Martha P Mims; Michael J Keating; George Carrum; Rammurti T Kamble; Catherine M Bollard; Adrian P Gee; Zhuyong Mei; Hao Liu; Bambi Grilley; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner; Gianpietro Dotti
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

5.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

Review 6.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Authors:  G Gross; T Waks; Z Eshhar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

8.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

Review 9.  The basic principles of chimeric antigen receptor design.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Cancer Discov       Date:  2013-04-02       Impact factor: 39.397

10.  CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Authors:  Renier J Brentjens; Marco L Davila; Isabelle Riviere; Jae Park; Xiuyan Wang; Lindsay G Cowell; Shirley Bartido; Jolanta Stefanski; Clare Taylor; Malgorzata Olszewska; Oriana Borquez-Ojeda; Jinrong Qu; Teresa Wasielewska; Qing He; Yvette Bernal; Ivelise V Rijo; Cyrus Hedvat; Rachel Kobos; Kevin Curran; Peter Steinherz; Joseph Jurcic; Todd Rosenblat; Peter Maslak; Mark Frattini; Michel Sadelain
Journal:  Sci Transl Med       Date:  2013-03-20       Impact factor: 17.956

View more
  1 in total

Review 1.  Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma.

Authors:  Piamsiri Sawaisorn; Korakot Atjanasuppat; Usanarat Anurathapan; Somchai Chutipongtanate; Suradej Hongeng
Journal:  Vaccines (Basel)       Date:  2020-12-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.